vs
GERMAN AMERICAN BANCORP, INC.（GABC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是GERMAN AMERICAN BANCORP, INC.的1.7倍（$219.9M vs $126.7M），GERMAN AMERICAN BANCORP, INC.净利率更高（28.2% vs -1.0%，领先29.2%），GERMAN AMERICAN BANCORP, INC.同比增速更快（39.7% vs 2.0%），GERMAN AMERICAN BANCORP, INC.自由现金流更多（$154.0M vs $16.8M），过去两年GERMAN AMERICAN BANCORP, INC.的营收复合增速更高（22.7% vs 8.0%）
German American Bancorp, Inc.（股票代码：GABC）是一家美国的银行控股企业，专注于提供多元金融服务，核心业务涵盖支付卡相关服务，总部位于纽约曼哈顿下城的巴特利公园城，在金融服务领域拥有成熟的业务布局。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GABC vs OFIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $126.7M | $219.9M |
| 净利润 | $35.7M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 34.6% | 0.2% |
| 净利率 | 28.2% | -1.0% |
| 营收同比 | 39.7% | 2.0% |
| 净利润同比 | 53.7% | 92.4% |
| 每股收益（稀释后） | $0.98 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $126.7M | $219.9M | ||
| Q3 25 | $126.5M | $205.6M | ||
| Q2 25 | $123.2M | $203.1M | ||
| Q1 25 | $111.1M | $193.6M | ||
| Q4 24 | $90.7M | $215.7M | ||
| Q3 24 | $88.5M | $196.6M | ||
| Q2 24 | $90.5M | $198.6M | ||
| Q1 24 | $84.1M | $188.6M |
| Q4 25 | $35.7M | $-2.2M | ||
| Q3 25 | $35.1M | $-22.8M | ||
| Q2 25 | $31.4M | $-14.1M | ||
| Q1 25 | $10.5M | $-53.1M | ||
| Q4 24 | $23.2M | $-29.1M | ||
| Q3 24 | $21.0M | $-27.4M | ||
| Q2 24 | $20.5M | $-33.4M | ||
| Q1 24 | $19.0M | $-36.0M |
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | 34.6% | 0.2% | ||
| Q3 25 | 34.6% | -8.3% | ||
| Q2 25 | 31.8% | -7.9% | ||
| Q1 25 | 12.0% | -25.2% | ||
| Q4 24 | 31.6% | -5.3% | ||
| Q3 24 | 29.0% | -9.6% | ||
| Q2 24 | 29.4% | -12.5% | ||
| Q1 24 | 27.6% | -15.6% |
| Q4 25 | 28.2% | -1.0% | ||
| Q3 25 | 27.7% | -11.1% | ||
| Q2 25 | 25.5% | -6.9% | ||
| Q1 25 | 9.5% | -27.4% | ||
| Q4 24 | 25.6% | -13.5% | ||
| Q3 24 | 23.8% | -13.9% | ||
| Q2 24 | 22.7% | -16.8% | ||
| Q1 24 | 22.6% | -19.1% |
| Q4 25 | $0.98 | $-0.05 | ||
| Q3 25 | $0.94 | $-0.57 | ||
| Q2 25 | $0.84 | $-0.36 | ||
| Q1 25 | $0.30 | $-1.35 | ||
| Q4 24 | $0.79 | $-0.76 | ||
| Q3 24 | $0.71 | $-0.71 | ||
| Q2 24 | $0.69 | $-0.88 | ||
| Q1 24 | $0.64 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $100.0M | — |
| 股东权益账面价值 | $1.2B | $450.0M |
| 总资产 | $8.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
| Q4 25 | $100.0M | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $114.6M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | $1.2B | $450.0M | ||
| Q3 25 | $1.1B | $442.5M | ||
| Q2 25 | $1.1B | $458.3M | ||
| Q1 25 | $1.0B | $458.3M | ||
| Q4 24 | $715.1M | $503.1M | ||
| Q3 24 | $744.6M | $525.9M | ||
| Q2 24 | $687.8M | $546.0M | ||
| Q1 24 | $655.3M | $570.3M |
| Q4 25 | $8.4B | $850.6M | ||
| Q3 25 | $8.4B | $832.6M | ||
| Q2 25 | $8.3B | $837.2M | ||
| Q1 25 | $8.4B | $823.1M | ||
| Q4 24 | $6.3B | $893.3M | ||
| Q3 24 | $6.3B | $867.9M | ||
| Q2 24 | $6.2B | $882.0M | ||
| Q1 24 | $6.1B | $906.0M |
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.16× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $154.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 121.6% | 7.6% |
| 资本支出强度资本支出/营收 | 4.2% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.46× | — |
| 过去12个月自由现金流最近4个季度 | $267.0M | $-1.3M |
8季度趋势，按日历期对齐
| Q4 25 | $159.3M | $27.7M | ||
| Q3 25 | $51.8M | $12.4M | ||
| Q2 25 | $26.9M | $11.6M | ||
| Q1 25 | $37.9M | $-18.4M | ||
| Q4 24 | $95.8M | $23.7M | ||
| Q3 24 | $24.5M | $11.7M | ||
| Q2 24 | $18.7M | $9.0M | ||
| Q1 24 | $23.9M | $-18.6M |
| Q4 25 | $154.0M | $16.8M | ||
| Q3 25 | $50.1M | $2.5M | ||
| Q2 25 | $26.2M | $4.5M | ||
| Q1 25 | $36.7M | $-25.1M | ||
| Q4 24 | $90.7M | $15.2M | ||
| Q3 24 | $23.0M | $6.3M | ||
| Q2 24 | $17.0M | $-360.0K | ||
| Q1 24 | $22.6M | $-29.1M |
| Q4 25 | 121.6% | 7.6% | ||
| Q3 25 | 39.6% | 1.2% | ||
| Q2 25 | 21.2% | 2.2% | ||
| Q1 25 | 33.0% | -13.0% | ||
| Q4 24 | 100.1% | 7.0% | ||
| Q3 24 | 26.0% | 3.2% | ||
| Q2 24 | 18.8% | -0.2% | ||
| Q1 24 | 26.9% | -15.4% |
| Q4 25 | 4.2% | 4.9% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 1.1% | 3.5% | ||
| Q4 24 | 5.6% | 4.0% | ||
| Q3 24 | 1.7% | 2.7% | ||
| Q2 24 | 1.8% | 4.7% | ||
| Q1 24 | 1.5% | 5.6% |
| Q4 25 | 4.46× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 3.61× | — | ||
| Q4 24 | 4.13× | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 0.91× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GABC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
